Dogwood Therapeutics, Inc.
DWTXNASDAQHealthcare● Active
$1.50
+$0.00(+0.00%)
Market Cap$2866706
P/E Ratio—
52W High$9.5
52W Low$1.28
Dogwood Therapeutics, Inc. (DWTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
DWTX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.15
Est. -$0.22 · +31.8%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
DWTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.13 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 14, 2026 | -$0.22 | -$0.15 | +31.8% | — | — | — |
| ▲ Q1 FY2026 | Mar 18, 2026 | -$0.86 | -$0.26 | +69.8% | — | — | — |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$1.23 | -$8.20 | -566.7% | — | — | — |
| ▼ Q3 FY2025 | Aug 13, 2025 | -$1.26 | -$1.99 | -57.9% | — | — | — |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.77 | -$4.21 | -446.8% | — | — | — |
| ▼ Q1 FY2025 | Feb 26, 2025 | -$1.36 | -$5.90 | -333.6% | — | — | — |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$1.18 | -$2.05 | -73.7% | — | — | — |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.13
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Beat
EPS Actual
-$0.15
EPS Est.
-$0.22
EPS Surpr.
+31.8%
Revenue
—
Q1 FY2026
Mar 18, 2026Beat
EPS Actual
-$0.26
EPS Est.
-$0.86
EPS Surpr.
+69.8%
Revenue
—
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$8.20
EPS Est.
-$1.23
EPS Surpr.
-566.7%
Revenue
—
Q3 FY2025
Aug 13, 2025Miss
EPS Actual
-$1.99
EPS Est.
-$1.26
EPS Surpr.
-57.9%
Revenue
—
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$4.21
EPS Est.
-$0.77
EPS Surpr.
-446.8%
Revenue
—
Q1 FY2025
Feb 26, 2025Miss
EPS Actual
-$5.90
EPS Est.
-$1.36
EPS Surpr.
-333.6%
Revenue
—
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$2.05
EPS Est.
-$1.18
EPS Surpr.
-73.7%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Q3 FY2027 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Q2 FY2027 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Q1 FY2027 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Q4 FY2026 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Q3 FY2026 | $-0.15 | $-0.15 | $-0.15 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | +31.8% | $1.86 | $1.98 | +6.45% |
| ▲ Q1 FY2026 | Mar 18, 2026 | +69.8% | $3.22 | $2.97 | -7.76% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -566.7% | $5.56 | $5.20 | -6.47% |
| ▼ Q3 FY2025 | Aug 13, 2025 | -57.9% | $4.85 | $4.80 | -1.03% |
| ▼ Q2 FY2025 | May 8, 2025 | -446.8% | $4.63 | $4.56 | -1.51% |
| ▼ Q1 FY2025 | Feb 26, 2025 | -333.6% | $5.01 | $5.12 | +2.20% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -73.7% | $4.45 | $4.45 | +0.00% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +28.6% | $4.68 | $4.47 | -4.49% |
Q2 FY2026+6.45%
Report Date
May 14, 2026
EPS Beat/Miss
+31.8%
Price Before
$1.86
Price After
$1.98
Q1 FY2026-7.76%
Report Date
Mar 18, 2026
EPS Beat/Miss
+69.8%
Price Before
$3.22
Price After
$2.97
Q4 FY2025-6.47%
Report Date
Nov 6, 2025
EPS Beat/Miss
-566.7%
Price Before
$5.56
Price After
$5.20
Q3 FY2025-1.03%
Report Date
Aug 13, 2025
EPS Beat/Miss
-57.9%
Price Before
$4.85
Price After
$4.80
Q2 FY2025-1.51%
Report Date
May 8, 2025
EPS Beat/Miss
-446.8%
Price Before
$4.63
Price After
$4.56
Q1 FY2025+2.20%
Report Date
Feb 26, 2025
EPS Beat/Miss
-333.6%
Price Before
$5.01
Price After
$5.12
Q4 FY2024+0.00%
Report Date
Nov 7, 2024
EPS Beat/Miss
-73.7%
Price Before
$4.45
Price After
$4.45
Q3 FY2024-4.49%
Report Date
Aug 8, 2024
EPS Beat/Miss
+28.6%
Price Before
$4.68
Price After
$4.47
Avg Beat Reaction-1.93%
Avg Miss Reaction-1.36%
Beat Rate3 / 8 quarters
Largest Move-7.76% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: DWTX ends December
Dogwood Therapeutics, Inc. (DWTX) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.15 — beating the analyst consensus of $-0.22 by +31.8%. DWTX has beaten EPS estimates for 2 consecutive quarters. The next DWTX earnings date is expected around September 1, 2026.
Each quarter, investors track DWTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. DWTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
DWTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
DWTX earnings · 5 questionsDogwood Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. DWTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; DWTX historically reports after market close (AMC).
DWTX earnings datewhen is DWTX earningsDWTX next earnings datewhen does DWTX report earningsDWTX earnings calendar
▸ Source: FMP · Dogwood Therapeutics, Inc. SEC filings · US GAAP · Dogwood Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026